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Abstract
Recent work reveals that the innate immune system is able to recognize self targets and initiate an
inflammatory response similar to that of pathogens. One novel example of this innate autoimmunity
is ischemia/reperfusion (I/R) injury, in which reperfusion of the ischemic tissues elicits an acute
inflammatory response activated by natural IgM (nIgM) binding to ischemia-specific self antigens,
which are non-muscle myosin heavy chains type II (NMHC-II) subtype A and C. Subsequently, the
complement lectin pathway is activated and eventually tissue injury occurs. Although earlier studies
in the intestinal model showed that the classical complement pathway did not initiate I/R injury, C1q
deposition was still observed in the local injured tissues by imaging analysis. Moreover, the
involvement of the alternative complement pathway became unclear due to conflicting reports using
different knockout mice. To explore the immediate downstream pathway following nIgM-ischemic
antigen interaction, we isolated the nIgM-ischemic antigen immunocomplexes from the local tissue
of animals treated in the intestinal I/R injury model, and examined the presence of initial molecules
of three complement pathways. Our results showed that mannan-binding lectin (MBL), the early
molecule of the lectin pathway, was present in the nIgM-ischemic Ag immunocomplex. In addition,
C1q, the initial molecule of the classical pathway was also detected on the immunocomplex.
However, Factor B, the early molecule in the alternative pathway, was not detected in the
immunocomplex. To further examine the role of the alternative pathway in I/R injury, we utilized
Factor B knockout mice in the intestinal model. Our results showed that Factor B knockout mice
were not protected from local tissue injury, and their complement system was activated in the local
tissues by nIgM during I/R. These results indicated that the lectin complement pathway operates
immediately downstream of the nIgM-ischemic antigen interaction during intestinal I/R.
Furthermore, the classical complement pathway also appears to interact with the of nIgM-ischemic
antigen immunocomplex. Finally, the alternative complement pathway is not involved in I/R injury
induction in the current intestinal model.
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Introduction
Ischemia/reperfusion (I/R) injury is a major complicating feature of many clinical disease
entities. Intestinal I/R is a devastating syndrome. Approximately one-third of episodes are acute
events and are responsible for most gastrointestinal ischemia-related deaths (mortality rate of
70–90%) (Brandt, 2003). Recent work reveals that the innate immune system is able to
recognize self-targets and initiate an inflammatory response in a manner similar to that
provoked by pathogens (Carroll and Holers, 2005; Zhang and Carroll, 2007a; Zhang and
Carroll, 2007b). One novel example of innate autoimmunity occurs in I/R injury (Carroll and
Holers, 2005; Zhang et al., 2008; Zhang et al., 2006a; Zhang et al., 2004; Zhang and Carroll,
2007a; Zhang and Carroll, 2007b; Zhang et al., 2006b; Zhang et al., 2006c). Studies of
intestinal, skeletal muscle, and heart I/R models showed that reperfusion of ischemic tissues
elicits an acute inflammatory response activated by natural IgM (nIgM) (Fleming et al.,
2002; Reid et al., 2002; Williams et al., 1999; Zhang et al., 2006b; Zhang et al., 2006c). Newer
reports further demonstrate that human nIgM, like that of mice, is capable of inducing I/R
injury in the murine intestinal model, suggesting that innate autoimmunity may operate under
pathogenic conditions in humans (Zhang et al., 2008). Isolation of a monoclonal natural IgM
that initiates I/R injury (Zhang et al., 2004) has led to the identification in two different tissues
of self-targets, which are nonmuscle myosin heavy chains type II (NMHC-II) subtype A and
C, (Zhang et al., 2006a). A recent study also suggested that aggregation of the actin cytoskeleton
during ischemia can lead to IgM-mediated tissue injury (Shi et al., 2008). New studies further
suggest that the natural IgM-ischemic antigen complex provides a binding site for mannan-
binding lectin (MBL), which subsequently leads to activation of complement and results in
tissue injury (Zhang et al., 2004; Zhang and Carroll, 2007b; Zhang et al., 2006c).
Three pathways leading to activation of the complement system have been identified: the
classical, the lectin, and the alternative pathways. Each is activated by different initiators but
all converge on C3 activation, which is followed by a common cascade (Carroll, 1998). The
classical pathway is initiated by antibody-antigen interaction followed by the activation of
complement C1 and downstream components (C4, C2, and C3). The alternative pathway is
activated by spontaneous hydrolysis of C3 which allows the binding of factor B (Janeway et
al., 2004). Some recent studies also suggested that properdin (factor P) may directly activate
the alternative pathway (Holt et al., 1990; Spitzer et al., 2007; Vuagnat et al., 2000). The lectin
complement pathway is triggered by MBL recognizing certain patterns of carbohydrate
structures (Gadjeva et al., 2004; Roos et al., 2003; Tsutsumi et al., 2005; Turner, 2003;
Worthley et al., 2005). MBL naturally exists in a complex with the MBL-associated serine
proteases (MASPs) (Matsushita and Fujita, 1992; Schwaeble et al., 2002; Stover et al., 1999;
Takahashi et al., 1999; Thiel et al., 1997). The MASPs are activated when MBL binds to a
fitting carbohydrate pattern, resulting in cleavage of the polypeptide chains of the MASPs
(Vorup-Jensen et al., 2000). The activated MASPs further cleave relevant substrates, i.e. C4
and C2 for MASP-2; C3 and C2 for MASP-1 (Hajela et al., 2002).
Although the classical complement pathway was ruled out to initiate I/R injury in the intestinal
model (Hart et al., 2005; Walsh et al., 2005; Zhang et al., 2006c), C1q deposition was still
observed in the local injured tissues by imaging analysis (Zhang et al., 2006c). Whether or not
C1q is involved in the nIgM–ischemic Ag immunocomplex is still unknown.
Studies of the role of the alternative pathway in I/R injury have generated conflicting reports.
An earlier report using Factor D knockout animals by Stahl et al suggested that the alternative
pathway plays an important role in intestinal I/R (Stahl et al., 2003). Later, the same group
using double knockout mice of Factor B and complement C2 came up in the opposite finding
(Hart et al., 2005).
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To identify the immediate downstream pathway following nIgM-ischemic antigen interaction,
we isolated the nIgM-ischemic antigen immunocomplexes from the local tissue of animals
treated in an intestinal I/R injury model, and investigated the presence of initial molecules of
the three complement pathways. To clarify the role of the complement alternative pathway in
I/R injury, we used Factor B knockout mice to examine local tissue damage and nIgM-
mediated complement activation in the intestinal model.
Materials and Methods
Animals and the intestinal model of ischemia reperfusion injury
Wild type BALB/c mice were purchased from the Jackson Laboratory (Bar Harbor, ME).
Factor B knockout mice were generated by Dr. Harvey R. Colten (Matsumoto et al., 1997) and
were kindly provided by Dr. Rick Wetsel (University of Texas). The Factor B−/− strain has
been bred onto the C57BL/6 background for at least 10 generations and maintained in the
animal facilities of The Rockefeller University. The Factor B−/− mice were genotyped in the
Steinman laboratory at The Rockefeller University. The surgical protocol for I/R was
performed as previously described (Zhang et al., 2004). Briefly, after anesthesia, a laparotomy
was performed, and a microclip (125g pressure, Roboz, Gaithersburg, MD) was applied to the
superior mesenteric artery. The ischemia-treated mice were kept in room temperature for 40
minutes. After the 40 minutes of ischemia the microclip was removed, and all animals were
kept warm during reperfusion. At the end of the experiment, the ischemic segment of the
intestine was harvested, washed with normal saline, and frozen for further analysis.
Isolation of nIgM-ischemic antigen immunocomplex and detection of initiating factors of
three complement pathways
We have developed a quantitative immunoassay to isolate the nIgM-ischemic Ag complex and
to detect the early complement factors in the immunocomplex (Fig.1). The intestine was thawed
and homogenized by sonication for 5 minutes in 1ml saline on ice. Tissue lysate was centrifuged
at 2000 g for 5 minutes and the supernatant was saved for subsequent analysis. Protein
concentration in the supernatant was determined by Bradford Assay (Biorad, Hercules, CA).
A 96-well flat-bottom immulon 2HB plate (Thermo, Waltham, MA) was coated with affinity
purified rabbit IgG specifically recognizing NMHC-II A (1μg/ml, Covance, Princeton, NJ) and
incubated overnight at 4°C. The plate was washed once and blocked with 1% BSA/0.05
Tween-20 (Calbiochem, San Diego, CA) in phosphate-buffered saline (PBS) for 2 hours at
room temperature. The plate was washed once again. Intestinal lysate was added to the coated
wells at a concentration of 12mg/ml, and incubated for 2 hours at room temperature to capture
the nIgM-ischemic antigen complex (overnight incubation at 4°C also worked for this assay).
The 12mg/ml concentration of intestinal lysates was determined as optimal by the results of
pilot experiments, in which lysates with different concentrations were tested in the assays. The
plate was then washed 3 times. To detect the bound natural IgM in the immunocomplexes,
alkaline phosphatase (AP)-labeled rabbit anti-mouse IgM (0.33μg/ml, Rockland, Gilbertsville,
PA) was added to the plate, and incubated for 1 hour at room temperature. The unbound
antibodies were washed out with 0.05% Tween-20/PBS, and 1mg/ml phosphatase substrate
(Sigma, St. Louis, MO) was added to develop color reaction. The optical density was
determined in a Multiscan microplate reader (Thermo, Waltham, MA). To detect if early
complement factors of any of the three complement pathways were to be found in the captured
immunocomplexes, biotinylated antibodies specific for MBL (clone 131-1,(Jensenius et al.,
2003); Hycult biotechnology, Canton, MA), and for C1q (Quidel, San Diego, CA), were used
as the detection antibody followed by the addition of streptavidin-conjugated with alkaline
phosphatase (0.19μg/ml, SouthernBiotech, Birmingham, AL). Horseradish peroxidase-
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conjugated goat anti-human Bb (Bb fragment EIA kit, part# A9566, Quidel, San Diego, CA)
was used as the detection antibody followed by the addition of the substrate.
A Pooled intestinal lysate from 13 I/R mice and from 11 sham treated mice was used as the
internal standard. The standard curve was produced using the optical densities (OD) of the
serially diluted the pooled lysates as x coordinates, and their protein concentrations (mg/ml)
as y coordinates in the curve fitting. The OD of individual sample was converted to the relative
amount according to the pooled standard lysates and then expressed as a ratio of per milligram
per milliliter of protein in the tested sample lysates (Unit/mg.ml−1). The presence of C3,
properdin, and IgG was also examined in the ischemic Ag immunocomplexes captured by the
above approach. To detect C3, goat anti-mouse C3 (0.2μg/ml, ICL, Newberg, OR) was used
as the primary detection antibody, followed by the secondary detection antibody of AP-labeled
rabbit anti-goat IgG (0.2μg/ml, Abcam, Cambridge, MA). To detect properdin, goat anti-
human factor P (properdin) (ART, Tyler, TX) was used as the primary detection antibody to
the captured ischemic Ag complex, followed by the secondary detection antibody of AP-
labeled rabbit anti-goat IgG (0.2μg/ml, Abcam, Cambridge, MA). As for IgG detection in the
captured immunocomplex, AP-labeled donkey anti-mIgG (0.12μg/ml, Jackson
ImmunoResearch, West Grove, PA) was used as the detection antibody. The rest of the ELISA
protocol followed the steps as described in the above section.
Binding specificity between the coating antibody and the self-antigen
To test for the specificity of the reaction of the coating antibody to the self-antigen, we carried
out negative control experiments for the quantification of the IgM-ischemic Ag complex and
detection of the initiating factors of the three complement pathways. Rabbit IgG against rat
IgG (Vector laboratories, Burlingame, CA) was used as the coating antibody on the 96-well
plates. The rest of experimental protocol followed the steps as described in the above section.
Histopathological and immunohistochemical analysis
Cryostat sections of intestinal tissues were stained with Hematoxylin and Eosin (H&E), blind-
coded by a different person, and examined by light microscopy for mucosal damage. The
pathology score was assessed based on a procedure developed by Zhang, which included a
direct inspection of all microvilli over a 4-cm stretch of jejunum as described (Zhang et al.,
2004).
To detect IgM deposition in the local tissues, cryosections were pretreated with 4%
paraformaldehyde (PFA) (J.T. Baker, Phillipsburg, NJ) /PBS and incubated with 2.5μg biotin-
labeled goat anti-mouse IgM (SouthernBiotech, Birmingham, AL) per ml of 1% BSA/0.01
Tween-20 /PBS for 2 hours, followed by staining with 4μg streptavidin-Alexa-568 (Molecular
Probes, Carlsbad, CA) per ml of 1% BSA/0.01 Tween-20 /PBS for 1 hour. The deposition of
C3 was detected by using 66μg FITC-labeled anti-C3 (Dako, Carpinteria, CA) per ml of 1%
BSA/0.01 Tween-20 /PBS. Sections were counterstained and mounted in ProLong Gold
Antifade Mounting Medium with 4', 6-diamidinio-2-phenylindole (DAPI) (Invitrogen,
Carlsbad, CA). Fluorescent images were made with an Olympus digital imaging system
(Olympus, Center Valley, PA).
Statistical analysis
All quantitative data were entered into a Microsoft Excel database and a two-sided student t-
test was used to analyze the statistical differences between the groups. The data were expressed
as mean ± standard error of the mean (SEM) and p<0.05 was considered to be statistically
significant.
Lee et al. Page 4
Mol Immunol. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Results
To identify the presence of early complement factors in the nIgM-ischemic antigen complex,
we developed an immunoassay to isolate the immunocomplexes from WT mice subjected to
intestinal I/R (Fig.1). Histopathological analyses confirmed that local tissues from I/R treated
WT mice had significant injury compared with those of sham controls (pathology score of I/
R group=19±2.8, n=27; pathology score of sham group=5±0.9, n=26; p=0.00003) (Fig.2a and
2b). Intestinal tissues from WT mice treated in the intestinal I/R model were homogenized to
release the potential immunocomplexes in the supernatant of the lysates. The ischemic self
antigen from the lysates, NMHC-II, was captured by the pre-coated anti-NMHC antibody, and
after washout of unbound components, the nIgM that bound to NMHC-II during the I/R
treatment was detected by anti-IgM antibody. Compared with samples from the sham control
mice, local tissues from I/R treated animals had significantly more nIgM bound to the NMHC-
II (Sham=14±1.6 Unit/mg.ml−1, n=21 vs. I/R=40±5.7 Unit/mg.ml−1, n=16, p=0.0005) (Fig.
3a).
To detect early complement factors in the nIgM-ischemic antigen complex, we modified the
above immunoassay by replacing the anti-IgM detection antibody with antibodies specific to
either C1q, MBL, or Factor B, which are the initial factors in each of the three complement
pathways. As expected, MBL, the early molecule of the lectin pathway, was detected in the
immunocomplex and significantly elevated in the intestinal tissues of I/R- treated mice
compared to those of sham-treated animals (Sham=10±1.6 Unit/mg.ml−1, n=21 vs. I/R=21±3.3
Unit/mg.ml−1, n=16, p=0.006) (Fig.3b). In addition, C1q, the initial molecule of the classical
pathway was also detected in the nIgM-ischemic antigen complex formed in local tissues of I/
R treated mice (Sham=10±3.2 Unit/mg.ml−1, n=21 vs. I/R=25±6.1 Unit/mg.ml−1, n=16,
p=0.042) (Fig.3c). However, there is no significant increase of Factor B, the early molecule in
the alternative pathway, present in the nIgM-ischemic Ag immunocomplex (Sham=10±3.2
Unit/mg.ml−1, n=6 vs. I/R=6±2.0 Unit/mg.ml−1, n=6, p=0.243) (Fig.3d).
We also carried out negative control experiments for the above quantification assays. The
coating antibody against NMHC was replaced with a nonspecific antibody of the same
immunoglobulin isotype (IgG), which was generated from the same animal species (rabbit).
The rest of the experimental protocol remained the same. The assays using the nonspecific
antibody did not distinguish between the sham-operated vs. the I/R treated groups (Fig.4).
Thus, these results provide support for the validity of our quantitative immunoassay for the
natural IgM- ischemic Ag complex.
To further investigate the involvement of the complement alternative pathway in intestinal I/
R injury induction, we examined complement C3 and properdin (factor P) in the
immunocomplexes. Spontaneous hydrolysis of C3 was reported as an activator for Factor B
and formation of C3(H2O)Bb, the fluid phase C3 convertase, further cleave more C3 for
activation. Properdin functions in the alternative path by stabilizing the fluid phase C3
convertase. Recent studies indicate that properdin can directly activate the alternative pathway
by binding sulfated glycoconjugates (Holt et al., 1990) and specific target surfaces (Spitzer et
al., 2007; Vuagnat et al., 2000). C3 was detected in the immunocomplex in the intestinal tissues
of I/R-treated mice (I/R=105±14 Unit/mg.ml−1, n=8, vs. Sham=45±19 Unit/mg.ml−1, n=8,
p<0.05) (Fig.5a). In contrast, no specific binding of factor P to the immunocomplex was
detected (Fig.5b).
Because IgG natural antibodies are known to activate the alternative pathway of complement
(Lutz, 2007), we investigated whether IgG was present in the immunocomplexes. Our results
showed no specific presence of IgG in the ischemic Ag immunocomplex (I/R=77±15 Unit/
mg.ml−1, n=8 vs., Sham=47±13 Unit/mg.ml−1, n=8, p=0.16) (Fig.5c).
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The role of Factor B was further studied in vivo by using Factor B-deficient (FB−/−) mice in
the intestinal I/R model. Morphological analysis showed that there was no significant reduction
of tissue injury in the FB−/− mice compared to the WT littermate FB+/+ controls (pathology
score of FB−/− group=10±3.1, n=11; pathology score of WT littermate group=16±6.4, n=5;
p=0.454) (Fig.6b). Immunohistochemical analysis further demonstrated that there were IgM
and C3 depositions in the I/R treated intestinal tissues of both FB−/− knockout mice and WT
littermate controls (Fig.7).
Discussion
Our results show that nIgM-ischemic antigen complex formed under I/R conditions (Fig. 3a),
and also indicate that early complement factors from the lectin and classical pathways, namely
MBL and C1q, were present in these nIgM-ischemic antigen immunocomplexes (Fig.3b and
3c).
The detection of C1q in the nIgM-ischemic antigen complex in this study complicated the
hypothesis of the initial mechanism of I/R injury induction. Earlier reports, including ours,
have shown that C1q knockout mice were not protected from I/R injury in intestinal models
(Hart et al., 2005; Zhang et al., 2006c), suggesting that the classical pathway of complement
does not play a dominant role in I/R injury induction. Nevertheless, in our earlier report, we
indeed noticed that C1q deposited and colocalized with IgM in the local tissues of I/R injured
WT mice by immunohistochemical staining (Zhang et al., 2006c), although no further study
was done at that time to identify if C1q was present in the immunocomplex. One possibility is
that C1q joins the I/R immunocomplex after MBL has been recruited to the nIgM-ischemic
antigen complex, thus acting as an auxiliary component in the amplification loop of
downstream complement activation.
Our study shows that the early component of the alternative complement pathway, Factor B,
was not detected in the ischemic antigen complex (Fig.3d). The ELISA assay for Bb fragment
of Factor B in this study used an antibody from an established commercial source (Quidel, CA)
which could detect Bb level as low as 0.018ug/ml. The ELISA system used in this study was
designed to capture the ischemic Ag immunocomplex formed in vivo, which has enabled us
to successfully detect complements from classical and lectin pathways, proving such an ELISA
system worked as expected. Thus, Factor B is unlikely to be actively involved in the formation
of the ischemic Ag immunocomplex (or if it might participate in the complex formation, the
level was too low and far beyond the lower limit of detection).
Our study further examined the presence of early molecules in the alternative pathway. A recent
view is that there are two models for alternative pathway: 1) the standard model by C3
hydrolysis, and 2) the properdin-directed model (Holt et al., 1990; Spitzer et al., 2007; Vuagnat
et al., 2000). The first model also needs properdin (Factor P) to stabilize the fluid phase C3
convertase, C3(H2O)Bb.
Our results showed that complement C3 was indeed present in the ischemic Ag complex, but
properdin was not. This suggests that properdin is not part of the ischemic Ag complex. Our
interpretation for C3 in the complex is that it is activated following the classical or lectin
pathways because C3 is known to be a common factor of all three complement pathways. The
possibility that the deposition of C3 in the ischemic Ag immunocomplex following the common
pathway may activate the alternative complement pathway in a second phase can not be ruled
out in this study.
Because IgG can potentially activate the alternative pathway through the formation of C3b2-
IgG complexes (Banda et al., 2008; Boxx et al., 2009; Lutz and Jelezarova, 2006; Otten et al.,
2009; Xiao et al., 2007), we also examined the presence of IgG in the ischemic Ag complex.
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Our results showed that IgG was not detected in the complexes. Fleming et al have previously
showed that natural IgG by itself does not initiate the I/R injury but could augment the natural
IgM mediated injury (Fleming et al., 2002). The absence of IgG in the ischemic Ag complex
in our current study confirms the previous view of IgG in I/R injury. Nevertheless, it is still
possible that natural IgG may bind to other self targets exposed by the initial attack through
the IgM mechanism (Fleming et al., 2004).
This study has provided in vivo evidence that knockout of Factor B neither significantly
protected the animals from intestinal I/R injury (Fig.6a and 6b), nor blocked the nIgM-mediated
complement activation (Fig.7). Factor B is the critical factor in the alternative pathway either
initiated by C3, properdin, or IgG. Thus, this study clarifies previous conflicting reports (Hart
et al., 2005; Stahl et al., 2003) and suggests that the alternative complement pathway does not
play an important role in intestinal I/R injury induction.
The publication claiming that Factor D knockout mice were protected from intestinal I/R injury
indeed generated controversy (Stahl et al., 2003), not only against findings by us and others
(Fleming, 2006), but even the later result from the same group using C2/fb knockout mice
(Hart et al., 2005). Careful examination of the study using Factor D knockout revealed some
drawbacks in the data which weaken the conclusion of that paper. First, the histological
protection of FD knockout mice was only demonstrated in 1 small area of the H&E staining
section with less than 20 microvilli, and no overall pathology scores were given to estimate
the degree of injury (the later C2/fb paper by the same group did include impression scores,
probably recognizing this flaw in the earlier report). We typically examine 200-400 microvilli
of a 4cm intestinal segment, and have developed a pathologic scoring system representing both
the severity and total number of injured microvilli (Zhang et al., 2006a; Zhang et al., 2004).
Second, the fluorescent staining of C3 in the FD knockout paper showed green fluorescent
staining over all types of cells in the positive control duodenum, which appeared to be non-
specific. We typically saw specific C3 deposition within the microvilli of jejunum as
demonstrated in our current study (Fig.7). Fluorescence on the outer epithelium of the intestine
particularly tends to be non-specific as food components often cause auto-fluorescent
background. The choice of the duodenum for C3 staining in FD paper is also very questionable
as the same group has been using the surgical protocol for jejunum ischemia and showed H&E
analysis in the jejunum (Stahl et al., 2003). It is known that the duodenum does not give
consistent pathology in the I/R model. Therefore, these drawbacks in the FD study severely
weaken the conclusion claimed in the FD study. It is unlikely that different genetic backgrounds
caused the controversy as they were using mice from C57BL/6J background in both the FD
knockout study and C2/fb knockout experiments. Our FB deficient mice also have C57BL/6
backgrounds.
However, our results do not exclude the possibility that the alternative complement pathway
might participate in a later phase of inflammatory response during intestinal I/R. For instance,
a recent publication indicated that although intact Factor H, an inhibitor of the alternative
pathway that competes with Factor B for C3b binding, was not able to protect against intestinal
I/R injury, a fusion protein of Factor H and complement receptor 2 could reduce local injury
and complement activation (Huang et al., 2008). Moreover, the complement alternative
pathway may be involved in I/R injury in other tissues. For example, some studies find that in
the kidney I/R injury the complement system is exclusively activated via the alternative
pathway, and selective inhibition of this pathway could protect the kidneys from ischemic acute
renal failure (Thurman and Holers, 2006; Thurman et al., 2003; Thurman et al., 2006).
However, others found that the MBL pathway is also involved in tissue injury in a kidney I/R
model (Moller-Kristensen et al., 2005). Thus, I/R injury may operate through multiple
mechanisms and different results in current literatures may reflect the complexity regarding
the models and strategies chosen for analysis.
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In summary, our study confirms the important role of the complement lectin pathway in
intestinal I/R injury induction, and suggests that the classical pathway may play an auxiliary
role in the current model. Our study further indicates that the alternative pathway plays only a
marginal role in intestinal I/R injury induction.
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Figure 1.
Schematic diagram of the immunoassay for the analytical isolation of the nIgM-ischemic Ag
complexes and the detection of the early complement factors in the immunocomplex. Plates
were coated with rabbit anti-NMHC-II A and intestinal lysates from I/R-treated or sham control
mice were added to the plates. To detect the nIgM in the immunocomplex, AP-labeled anti-
IgM antibody was used. To detect bound complement factors deposited on the
immunocomplex, specific antibodies for MBL, C1q, or Factor B were used instead of the anti-
IgM antibody.
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Figure 2.
Tissue injury following I/R. Local tissues from I/R-treated WT mice had significant injury
compared with those of sham controls. a) Representative intestinal sections from sham-treated
and I/R-treated WT mice were stained with H&E. Arrows indicate typical pathology features
of microvilli injury. Original magnification= x200. b) Pathology scores were assigned based
on the degree of microvilli injury as described in Methods. Results are mean ± standard error
of the mean (SEM), and asterisks indicate statistical significance (Student's t test; p<0.01).
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Figure 3.
Isolation of nIgM-ischemic Ag immunocomplex and detection of initiating factors of three
complement pathways. The nIgM-ischemic Ag complexes were captured in antibody-coated
microtiter wells as described in Figure 1. a) Detection of nIgM in the captured
immunocomplexes from intestinal tissues. b) Detection of MBL. c) Detection of C1q. d)
Detection of Bb fragment of Factor B. Asterisks indicate statistical significance (Student's t
test; * p<0.05 **p<0.01). Error bars indicate SEM.
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Figure 4.
Negative control experiments for the quantification of the IgM-ischemic Ag complex and
detection of the initiating factors of the three complement pathways. The anti-NMHC-II
antibody was replaced with rabbit antibody against rat IgG as the coating antibody on the 96-
well plates. The rest of the experimental protocol followed the steps as described in Figure 3.
Statistical analysis showed no significant differences between sham vs. I/R treated groups
(Student's t test; p>0.05). Error bars indicate SEM.
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Figure 5.
Detection of early complement factors of the alternative pathway and IgG natural antibody.
The nIgM-ischemic Ag complexes were captured in antibody-coated microtiter wells as
described in Figure 1. a) Detection of C3 in the captured immunocomplexes from intestinal
tissues. b) Detection of Factor P. c) Detection of IgG. Asterisks indicate statistical significance
(Student's t test; * p<0.05). Error bars indicate SEM.
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Figure 6.
Tissue injury in factor B KO mice. No significant reduction of tissue injury was seen in the
FB−/− mice compared to the WT littermate controls (FB+/+). a) Representative intestinal
sections from I/R-treated FB−/− and FB+/+ mice were stained with H&E. Arrows indicate
typical pathology features of microvilli injury (x200 magnification). b). Pathology scores and
statistical significance were analyzed as described in Methods. Error bars indicate SEM.
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Figure 7.
IgM and C3 in tissue following I/R. FB−/− mice were not protected from intestinal reperfusion
injury. IgM and complement C3 were present within the microvilli of I/R-treated FB+/+ and
FB−/− mice. Sections i, ii, and iii were representative images from sham-treated FB+/+ mice.
Sections iv, v, and vi were representative images from sham-treated FB−/− mice. Sections vii,
viii, and ix were representative images from I/R-treated FB+/+ mice. Sections x, xi, and xii were
representative images from I/R-treated FB−/− mice. Sections i, iv, vii, and x were stained with
anti-IgM-biotin followed by streptavidin-Alexa-568 (red). Sections ii, v, viii, and xi were
stained with anti-C3-FITC (green). Sections iii, vi, ix, and xii were merged images of IgM and
C3 to demonstrate the colocalization (yellow). All sections were counterstained with DAPI
(violet). Original magnification=x400.
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